Bringing single-cell protein blots to the organoid's scarce cells

What the work claims

This is a primary methods paper with a demonstration dataset. Single-cell western blotting (scWB) separates each cell's proteins by molecular mass before probing them, which lets it distinguish protein variants that antibodies alone cannot tell apart. Its Achilles heel has been loading: cells are dropped into microwells by gravity and settle according to Poisson statistics, so getting one cell per well requires starting from roughly a million cells and still leaves most wells empty or wrong. That input demand rules out precious, cell-limited specimens, which is precisely what a patient-derived organoid (PDO) is.

AutoBlot swaps gravity settling for a piezoelectric robotic dispenser that places cells into sub-100-micron wells one at a time under image guidance. The reported gains are large and specific: about 98 percent single-cell occupancy from as few as 10,000 starting cells, a roughly hundredfold reduction in required input, with single-cell loading exceeding the Poisson expectation by factors of 31 to 904 across the concentrations tested, and deterministic one-cell-one-bead co-loading exceeding Poisson by nearly five orders of magnitude.¹ Applied to breast PDOs from seven donors, roughly 1,100 single cells across a five-protein panel, the method recovers known mammary biology and adds detail that bulk and antibody-only methods miss.

How it works

The panel is standard mammary lineage fare: the surface markers CD49f and EpCAM, the cytokeratins K14 and K19, and estrogen receptor (ER). Because scWB resolves by mass, the authors could see two ER bands in a subset of cells, a full-length species near 66 kDa and a shorter one near 46 kDa. The authors report that this smaller species lacks part of the AF-1 transactivation domain, has distinct transcriptional activity, and has been linked to tamoxifen resistance. Detecting it cell by cell in a primary specimen, rather than inferring an average, is the clearest argument for why mass resolution earns its keep here: an antibody-binding-only readout such as mass cytometry would report "ER present" and miss the split.

The genotype comparison is the second pillar. Among the donors, two carried BRCA1 germline mutations and four did not (one RAD51C carrier was excluded). BRCA1-mutant PDOs showed a markedly expanded luminal-progenitor-like fraction, 55.6 percent against 26.2 percent, matching prior sorting-based descriptions of BRCA1 tissue, and additionally showed elevated per-cell ER and EpCAM, a quantitative layer that surface-marker sorting alone cannot provide. Because the separated proteins are archived in the gel, the same array can be reprobed or excised for mass-spectrometry follow-up, and the deterministic cell-and-bead pairing opens the door to barcoded sequencing and ligand-receptor assays on the same platform.

Where a skeptic should push

The load-bearing assumption is that a per-cell signal reflects per-cell biology, and the paper itself supplies the counterexample. Pre-menopausal PDOs showed higher ER than post-menopausal ones, but the pre-menopausal cells were also significantly larger, and the authors concede the ER difference is "at least partly attributable to greater cell volume and total protein content." Signal scales with how much protein a cell contains, so any comparison across conditions that also differ in cell size can manufacture an apparent expression difference out of geometry. That is not a fatal flaw, it is a discipline requirement, but it is easy to forget when the output looks like a clean per-cell number.

The scope is also modest and should be read as such. Seven donors, only two of them BRCA1 carriers, five proteins, about 1,100 cells; the ER call was validated at 95 percent sensitivity and 97 percent specificity but with per-organoid false-negative rates as high as 14.8 percent, and total throughput remains well below droplet methods, which the authors do not hide. So "BRCA1 raises ER and EpCAM" is a two-donor observation, not a population fact; with only two mutant donors, a per-cell significance value also risks treating cells as independent replicates when the real unit is the donor. The proteoform work, likewise, is a proof of resolution rather than a resistance biomarker study.

Reading the subclones a bulk assay averages out

For organ models and the drug discovery built on them, the direct opportunity is a readout that sees heterogeneity a bulk lysate destroys. Drug response in a PDO is rarely uniform; it is the rare, pre-existing subpopulation that survives and regrows. A method that resolves a resistance-associated ER proteoform one cell at a time, in the small samples a PDO actually provides, is a tool for finding those subclones before a screen declares a compound a clean win. That this arrives as regulators lean toward organoid evidence under the FDA Modernization Act 2.0 makes the timing more than incidental: single-cell, mass-resolved protein data is exactly the sort of mechanistic support a non-animal model needs to be trusted.

The non-obvious implication is subtler and more valuable than the headline method, and it is a warning aimed at every organoid screen, not just this one. When the authors classified the same cells by surface markers (CD49f, EpCAM) and by intracellular cytokeratins (K14, K19), the two schemes disagreed systematically, with surface markers over-calling basal-like cells. One candidate explanation they raise is that CD49f, which is integrin alpha-6, binds laminin, and laminin makes up roughly 60 percent of the basement-membrane extract that PDOs are grown in. In other words, a marker routinely used to bin cells for analysis may be reporting engagement with the culture matrix rather than an intrinsic lineage state. The authors are careful to hold this as only one possibility, since the two marker sets might instead be capturing genuinely different lineage features; but the matrix reading is the one that should worry anyone stratifying a screen by surface markers. That is the generalization-failure trap in a single experiment: a property credited to the tissue can belong to the gel it was grown in. The dual-use edge is that the same instrument that exposes the artifact can be misread to entrench it, because per-cell numbers look authoritative even when a size confound or a matrix confound is doing the talking. The honest use of AutoBlot is therefore two-sided: mine it for the drug-relevant subclones bulk assays hide, and use its ability to cross-check surface against intracellular measurements to audit whether the markers a screen relies on are measuring the cell or the scaffold, with cell-volume normalization applied before any expression difference is believed.

The bottom line

Established: the loading method delivers what it claims, roughly 98 percent single-cell occupancy from about 10,000 cells, and on breast PDOs it recovers known BRCA1-associated lineage shifts and resolves ER proteoforms that antibody-only methods blur together. Hypothesis, still open: that single-cell proteoform profiling of organoids will actually improve drug-response prediction. Confirming that needs a proteoform-defined subpopulation shown, prospectively and with cell-size normalization, to track differential response to a drug; it would be undercut if the discordances and expression shifts the method surfaces turn out to be dominated by cell-volume and matrix-binding artifacts rather than biology. Either way, the paper's quiet contribution, that a widely used surface marker may be reading the culture, is a caution the whole field should carry forward.